Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Weigand, K; Schnitzler, P; Schmidt, J; Chahoud, F; Gotthardt, D; Schemmer, P; Stremmel, W; Sauer, P.
Cytomegalovirus infection after liver transplantation incidence, risks, and benefits of prophylaxis.
Transplant Proc. 2010; 42(7):2634-2641
Doi: 10.1016/j.transproceed.2010.04.025
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Schemmer Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Cytomegalovirus (CMV) infection and related disease is a feared complication after liver transplantation. Antiviral prophylaxis is recommended in clinical practice guidelines depending on the CMV status of both donor and recipient as well as the individual risk profile. We retrospectively analyzed 211 liver transplant recipients with respect to the incidence of CMV infection after transplantation, the influence of donor and recipient CMV status, and the effect of antiviral prophylaxis. In addition, the underlying liver disease and immunosuppressive regimen were compared with the incidence of CMV infection. Patients were divided into 4 groups according to CMV donor/recipient (D/R) profile: group A (D-/R-) 28 patients (13.3%), group B (D-/R+) 64 patients (30.3%), group C (D+/R+) 79 patients (37.4%), and group D (D+/R-) 40 patients (19.0%). CMV infection was observed in 17.9%, 29.7%, 24.1%, and 22.5% of the patients, respectively, with no significant difference in infection rates between the groups. CMV infection occurred in 5 patients (17.9%) in the presumed low-risk profile (group A), despite an antiviral prophylaxis in 4 out of these 5 patients. In contrast, CMV infection occurred in only 9/40 patients (22.5%) in the presumed high-risk profile (group D). The most frequent infection rates were found in groups B and C (R+ groups). After successful treatment of CMV infection, no recurrence was detected. Underlying liver disease or immunosuppressive protocol had no influence on CMV infection. Approximately one fourth of patients will acquire CMV infection after liver transplantation independent of donor/recipient status. Surprisingly, antiviral prophylaxis does not seem to be sufficient to reduce this proportion of patients, either in presumed high-risk or in presumed low-risk situations. 2010 Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antigens, Viral - analysis
- Antiviral Agents - therapeutic use
- Cytomegalovirus - genetics
- Cytomegalovirus Infections - drug therapy
- Cytomegalovirus Infections - epidemiology
- Cytomegalovirus Infections - prevention & control
- DNA, Viral - genetics
- DNA, Viral - isolation & purification
- Drug Therapy, Combination -
- Female -
- Gene Amplification -
- Humans -
- Immunosuppressive Agents - therapeutic use
- Incidence -
- Liver Diseases - classification
- Liver Diseases - surgery
- Liver Transplantation - adverse effects
- Male -
- Middle Aged -
- Phosphoproteins - analysis
- Polymerase Chain Reaction - methods
- Risk Assessment -
- Tissue Donors -
- Viral Matrix Proteins - analysis